VYNE Therapeutics Inc. (ticker: VYNE) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of VYNE's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. VYNE reported $570K in revenue and -$26.48M for the period ending 2025-12-31, with operating cash flow of -$33.12M. Cash and equivalents stood at $24.03M (up 20.6% year-over-year). Total assets of $30.16M exceed total liabilities of $2.40M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
VYNE Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for VYNE Therapeutics Inc. (VYNE) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.